Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

844
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
844
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

487
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
487
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

682
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
682
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

422
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
422

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stroke and its consequences: protocol and pilot data of the observational Berlin Long-term Observation of Vascular Events (BeLOVE) stroke stratum.

BMJ neurology open·2026
Same author

Serum inflammatory proteomic signatures define chronic inflammatory demyelinating polyneuropathy and inform on disease activity.

EBioMedicine·2026
Same author

Infarct-associated oligoclonal T cell expansion in chronic experimental stroke across age, sex, and models.

Experimental neurology·2026
Same author

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

Brain : a journal of neurology·2026
Same author

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

Journal of neurology·2026
Same author

Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

Therapeutic advances in neurological disorders·2026
Same journal

Public Health Response to Clade Ib Mpox with Multiple Exposures in Congregate Living Settings - New Hampshire, February 2025.

NEJM evidence·2026
Same journal

Berberine-Ursodeoxycholate - Bringing Traditional Chinese Medicine to Our World.

NEJM evidence·2026
Same journal

Outbreak of Legionnaires' Disease Associated with Cooling Tower Systems in Central Harlem.

NEJM evidence·2026
Same journal

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026
Same journal

A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.

NEJM evidence·2026
Same journal

Evidence for Evidence-Based Medicine - A Call for Some Theory and a New Problem.

NEJM evidence·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2025

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.7K

Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.

Tuan Vu1, Andreas Meisel2, Renato Mantegazza3

  • 1University of South Florida Morsani College of Medicine, Tampa.

NEJM Evidence
|February 6, 2024
PubMed
Summary
This summary is machine-generated.

Ravulizumab offers rapid and sustained symptom improvement for generalized myasthenia gravis (gMG) patients. This complement inhibitor showed significant benefits in daily activities and muscle strength without increasing adverse events.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

13.7K

Related Experiment Videos

Last Updated: Jul 4, 2025

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.7K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

13.7K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder.
  • Autoantibodies targeting acetylcholine receptors (AChR) activate complement, causing neuromuscular junction damage.
  • Current treatments aim to manage symptoms and immune response.

Purpose of the Study:

  • To evaluate ravulizumab, a C5 complement inhibitor, for treating anti-AChR antibody-positive gMG.
  • To assess the efficacy and safety of ravulizumab compared to placebo over 26 weeks.

Main Methods:

  • A randomized, double-blind, placebo-controlled, multinational trial.
  • 175 patients with anti-AChR antibody-positive gMG were randomized (1:1) to receive intravenous ravulizumab or placebo.
  • Treatment involved a loading dose followed by maintenance doses every 8 weeks for 26 weeks.

Main Results:

  • Ravulizumab demonstrated statistically significant improvements in patient-reported MG-ADL scores (–3.1 vs. –1.4; P<0.001) and clinician-reported QMG scores (–2.8 vs. –0.8; P<0.001) compared to placebo.
  • Improvements were observed rapidly within one week and sustained through 26 weeks.
  • A greater proportion of ravulizumab-treated patients (30.0%) achieved a ≥5-point improvement in QMG scores versus placebo (11.3%; P=0.005).

Conclusions:

  • Ravulizumab provides rapid, sustained, and clinically meaningful improvements in gMG.
  • The safety and tolerability profile of ravulizumab supports its use in adults with anti-AChR antibody-positive gMG.
  • Ravulizumab represents a promising therapeutic option for complement-mediated gMG.